A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 ...

Real-world data show that the GLP-1 receptor agonists semaglutide and tirzepatide not only manage blood sugar and weight but also mirror their heart-protective effects from clinical trials in everyday ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The principal finding ...